ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1936

Prospective Analysis of Flow Velocity of the Central Retinal Artery in Newly Diagnosed Patients with Giant Cell Arteritis with Visual Symptoms and Controls

Lara Burg1, Katharina Reinking2, Peter Brossart3, Robert Finger2, Charlotte Behning4 and Valentin Schaefer5, 1Clinic for Internal Medicine III, Department of Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, 2Department of Ophthalmology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, 3Clinic for Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, 4Institute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany, 5Clinic of Internal Medicine III, Department of Oncology, Hematology and Rheumatology, University Hospital Bonn, Germany, Bonn, Nordrhein-Westfalen, Germany

Meeting: ACR Convergence 2020

Keywords: giant cell arteritis, Ultrasound

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2020

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Giant cell arteritis (GCA) is the most common form of systemic vasculitis in patients aged 50 years and older.1 Visual symptoms as amaurosis and temporary or permanent loss of visual field secondary to optic nerve ischemia are common manifestations.2 The role of ultrasound in diagnosis of GCA is known.3 Transocular ultrasound of the central retinal artery in GCA patients with visual symptoms has not yet been examined.

Methods: Prospective analysis of flow velocities of the central retinal artery in newly diagnosed GCA patients with visual symptoms and eye-healthy controls. Visual symptoms were defined as amaurosis and temporary or permanent loss of visual field. For each eye, peak systolic values (PS) and end-diastolic values (ED) were recorded.

Results: We included 27 newly diagnosed consecutive GCA patients with visual symptoms (GCA-group) and 25 eye-healthy controls. Thirty of 54 eyes (55%) of 27 GCA patients were symptomatic. The control group consisted of 50 central retinal arteries of 25 eye-healthy individuals. Mean age and gender distribution was 75 years (SD± 8.1) with 17 females (63 %) in the GCA group and 67 years (SD± 8.9) with twelve females (48%) in the control group, respectively. Mean flow velocity of the central retinal artery was in 10.9 cm/s (SD± 4.6) in PS and 3.5 cm/s (SD± 1.5) in ED in the GCA group, while values of 14.4 cm/s (SD± 3.2) in PS and 5.1 cm/s (SD± 1.6) in ED were observed in the control group. Mean reduction in flow velocity in the GCA-group was 3.5 cm/s (p-value 0.001) in PS and 1.6 cm/s (p-value 0.000099) in ED, therefore highly significant. Figure 1 shows an ultrasound image of a pathological flow velocity of the central retinal artery in GCA. Figure 2 displays differences in flow velocities between the two groups.

Conclusion: In GCA patients with visual symptoms, a significant reduction of flow velocities of the central retinal artery compared to the eye-healthy control group was observed. Longitudinal data will show, if the flow velocities normalized under treatment.

References

  1. Warrington KJ, Matteson EL. Management guidelines and outcome measures in giant cell arteritis (GCA). Clin Exp Rheumatol 2007;25:137–41.
  2. Chean CS, Prior JA, Helliwell T, et al. Characteristics of patients with giant cell arteritis who experience visual symptoms. Rheumatol Int 2019;39:1789–96.
  3. Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis 2018;77:636–43.

Figure 1. Transocular ultrasound of an affected eye in giant cell arteritis with reduced flow velocities.

Figure 2: Differences in peak systolic (PS) and end-diastolic (ED) flow between the two groups. GCA-group: Patients with GCA and visual symptoms Control-group: eye-healthy control patients


Disclosure: L. Burg, None; K. Reinking, None; P. Brossart, None; R. Finger, None; C. Behning, None; V. Schaefer, None.

To cite this abstract in AMA style:

Burg L, Reinking K, Brossart P, Finger R, Behning C, Schaefer V. Prospective Analysis of Flow Velocity of the Central Retinal Artery in Newly Diagnosed Patients with Giant Cell Arteritis with Visual Symptoms and Controls [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/prospective-analysis-of-flow-velocity-of-the-central-retinal-artery-in-newly-diagnosed-patients-with-giant-cell-arteritis-with-visual-symptoms-and-controls/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prospective-analysis-of-flow-velocity-of-the-central-retinal-artery-in-newly-diagnosed-patients-with-giant-cell-arteritis-with-visual-symptoms-and-controls/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology